Congratulations to Luca Bartolini for his American Epilepsy Society grant

In Uncategorized by Kristin Loomis

Luca Bartolini, MD, a neurologist with Children’s National, was awarded a $50,000/year early career grant administered by the American Epilepsy Society and supported by the Epilepsy Foundation for a study of viral and inflammatory causes of epilepsy. The research will be conducted at the National Institute of Neurological Diseases and Stroke (NINDS), NIH, where Dr. Bartolini will become an Epilepsy Fellow. His mentors will include Steve Jacobson, PhD, Chief, Viral Immunology Section, as well as William D. Gaillard, MD, Chief, Division of Child Neurology, Epilepsy, Neurophysiology and Critical Care Neurology, Children’s National and Professor of Neurology, George Washington University, and William H. Theodore, MD, Chief, Clinical Epilepsy Section, NINDS. Luca Bartolini, MD and new  Epilepsy Fellow, NINDS/NIH Luca Bartolini, MD …

Mystery particles: What is clinging to these HHV-6A virions?

In Uncategorized by Kristin Loomis

Nobel prize winning virologist Harald zur Hausen sent our scientific director Dharam Ablashi the attached electron microscope image of HHV-6A (GS) virions that were propagated in an HSB2 cell line and would like help in identifying the multiple small particles attached to the viral envelope shown in the photograph below. Zur Hausen reports that the particles did not react to HHV-6 or any other monoclonal antibodies. The particles appear to have diameters of about 40 nm. Do you have any thoughts on what they might be? Yasuko Mori and Koichi Yamanishi published a paper in 2008 indicating that HHV-6 acquires its envelope via a multivesicular body or exosome pathway (Mori 2008). Could these small particles be exosomes? Another possibility suggested …

HHV-6 DR6/7 “oncogene” monoclonal antibodies for cancer studies

In Uncategorized by Kristin Loomis

The HHV-6 Foundation has developed this mAb, with the help of Louis Flamand, PhD and it is now available at the Foundation Repository. This oncoprotein mAb has been tested by numerous scientists and appears to be better than antibodies against other proteins for detecting the presence of HHV-6 in tumors. It works for immunohistochemistry as well as western blots and detects both HHV-6A and HHV-6B. The DR-7 oncoprotein was used to identify HHV-6 in the  Reed-Sternberg cells of Hodgkin’s lymphoma tumors, primarily in the nodular sclerosis subset, by Lacroix et al in 2010. In 2012, Professor David Hudnall’s group at Yale confirmed that HHV-6B was localized in Reed-Sternberg cells in the nodular sclerosis subset of Hodgkin’s lymphomas (Siddon 2012). HHV-6 …

View Post

HHV-6, EBV and CMV found in GI tract cancers

In All, Liver Disease, Uncategorized by Kristin Loomis

A group from Washington University used a bioinformatics system called VirusScan to analyze RNA-Seq data sets from 6,813 human tumors compared to those of adjacent normal tissue. Tumor samples representing 23 different forms of cancer were analyzed. HHV-6, EBV and CMV were found at significantly high levels in GI tract cancer tissue.

Conference Videos

In Uncategorized by Kristin Loomis

Thank you to the presenters who agreed to make their presentations at the 9th International Conference on HHV-6 & 7 available to others. HHV-6 ANTIVIRAL THERAPY The Difficult Path Towards an HHV-6 Therapy Lieve Naesens, PhD, Laboratory of Virology and Chemotherapy, Rega Institute, KU Leuven, Belgium DIAGNOSTICS Diagnostic Tools and Algorithms for HHV-6 Infections in Immunocompromised Patients Agnes Gautheret Dejean, MD, PhD, Groupe Hospitalier Pitie-Salpetriere, France Detection of HHV-6B Reactivation in Hematopoietic Cell Transplant Recipients with Inherited Chromosomally Integrated HHV-6A by Droplet Digital PCR Ruth Hall-Sedlak, PhD, University of Washington, USA HHV-6 in TRANSPLANTATION HHV-6 Disease in Immunocompromised Patients Danielle Zerr, MD, Children’s Hospital of Seattle, University of Washington Guidelines for Treatment of HHV-6 Infections in Immunocompromised Patients Per Ljungman, …

HHV-6 status determines effectiveness of interferon treatment in Multiple Sclerosis

In All, Multiple Sclerosis, Uncategorized by hhv6foundation

The administration of immune agents to patients (known as Interferon-Beta-1b, or IFN-beta, therapy) has been widely used in the treatment and maintenance of multiple sclerosis (MS). Additionally, it is known that the risk of MS exacerbation is much higher in patients with active HHV-6 infection than in patients with a latent infection of the virus (Lafuente 2006, 2007; Chapenko 2003). In this new study from Madrid, researchers examined the effectiveness of IFN-1b therapy in multiple sclerosis patients with active HHV-6 infection. By monitoring the HHV-6 DNA levels of MS patients undergoing IFN-beta therapy, investigators were able to find that patients with active HHV-6 infection had a higher risk of severe MS relapse and poor response to IFN-beta therapy than patients …